Feature | March 20, 2009| Dave Fornell

If Radial Access Helps Increase Patient Safety, Why Aren’t More Doctors Using It?

During TCT 2009 this past fall in Washington D.C. I had the chance to listen to Shigeru Saito, M.D., FACC, ShonanKamakura General Hospital, Sapporo, Japan, explain reasons why he feels transradial artery access for interventional procedures is better than the U.S. standard of femoral access. Dr. Shigeru is among the biggest advocates in the world for transradial access, and is a self-described transradial intervention (TRI) evangelist. Living up to that title, he travels the globe each year to spread the word about the benefits of TRI and train physicians. Last year alone he visited 35 countries.

The first TRI was attempted in 1992. Dr. Shigeru said he started using the procedure in 2004 and since has become its biggest proponent. He advocates radial access as a way to help cut door-to-balloon times, because he says once doctors get familiar with TRI they can perform procedures faster than femoral access. He also said from his experience there is a high instance of complications using femoral access — primarily bleeding and incision site infection.

These same safety issues were highlighted in a recent meta-analysis of data on patients who underwent interventional procedures using either the femoral or radial access techniques. The study was published online in November in the American Heart Journal. The study found radial access significantly decreases risk of major bleeding compared to femoral access. Data also showed a trend toward fewer deaths and ischemic events using radial access.

Sanjit S. Jolly, M.D., of McMaster University in Hamilton, Canada and fellow researchers searched MEDLINE, EMBASE and CENTRAL from 1980 to April 2008 and conference abstracts from 2005 to April 2008 to identify randomized trials comparing radial vs. femoral access and examined cases for major bleeding, death, myocardial infarction and procedural times. They found 21 randomized trials with more than 5,400 patients. Their analysis showed radial access offered a significant reduction in major bleeding events and led to better outcomes compared to femoral access. Radial access also led to shorter hospital stays, the researchers found.

While these numbers seem promising, TRI accounts for a small number of the overall procedures conducted worldwide. In the U.S. the technique is rarely used and there is a lot of debate among American doctors about it. Dr. Shigeru classified the debate whether to use TRI as a fight between young and old interventionalists.

One of the arguments against using the access method has been hand ischemia induced by the procedure. There is also a steep learning curve to master the radial access technique, which is not taught at most U.S. medical schools.

Another reason why TRI has not been well received in the U.S. may be based on patient preferences. They generally don’t want scars on their wrists, which are much more visible than the groin. Second, it was pointed out in the TCT session patients need to be more heavily sedated because they tend to fight clinicians who are attempting to puncture their wrists.

We would be interested in hearing back from cardiologists who have attempted radial access and discontinued its use, and from those who adopted it as their preferred access method. My e-mail is [email protected]

Related Content

PCI, operator volume, China study, JACC, outcomes
News | Cath Lab| October 27, 2016
Volume matters when it comes to who does certain procedures to removing heart-attack causing blockages from arteries,...
Corindus, Corpath, robotic navigation, Robotic PCI, CorPath GRX
Technology | October 27, 2016
October 27, 2016 — Corindus Vascular Robotics Inc. announced it received 510(k) clearance from the U.S.
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics
Feature | Cath Lab| October 27, 2016 | Dave Fornell
The volume of information attendees receive at the annual Transcatheter Cardiovascular Therapeutics (TCT) interventio
Philips, TCT 2016, image guidance technologies, iFR, HeartNavigator
News | Cath Lab| October 26, 2016
Philips recently announced its latest image guidance solutions to be featured at the 2016 Transcatheter Cardiovascular...
Medtronic, CoreValve Evolut R, TAVR system, 34 mm valve, FDA approval, largest in the U.S.
Technology | Heart Valve Technology| October 26, 2016
Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve Evolut R 34...
medicare bundled cardiac payments, CMS cardiology payments
Feature | Business| October 24, 2016 | By John W. Meyer, MPH, FACHE
(Editor’s note: This is the second part of a two-part series on the proposed Medicare five-year demonstration for
bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system


Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Overlay Init